Related Experiment Video
Updated: Feb 23, 2026

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells MSCs
Published on: December 24, 2015
Inhibitory effect and molecular mechanism of mesenchymal stem cells on NSCLC cells
Mengwu Pan1, Lingling Hou2, Jingsi Zhang1
1College of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, 100044, People's Republic of China.
Abstract:
Non-small-cell lung cancer (NSCLC) is still the main threat of cancer-associated death. Current treatment of NSCLC has limited effectiveness, and unfortunately, the prognosis of NSCLC remains poor. Therefore, a novel strategy for cancer therapy is urgently needed. Stem cell therapy has significant potential for cancer treatment. Mesenchymal stem cells (MSCs) with capacity for self-renewal and differentiation into various cells types exhibit the feature of homing to tumor site and immunosuppression, have been explored as a new treatment for various cancers. Studies revealed that the broad repertoire of trophic factors secreted by MSCs extensively involved in the interplay between MSCs and tumor cells. In this study, we confirmed that MSCs do have the paracrine effect on proliferation and migration of NSCLC cells (A549, NCI-H460, and SK-MES-1). Co-culture system and conditioned medium experiments results showed that soluble factors secreted by MSCs inhibited the proliferation of NSCLC cells in vitro. The scratch assay showed that conditioned medium of MSCs could suppress the migration of NSCLC cells in vitro. Western blot results showed that the expression of proteins relevant to cell proliferation, anti-apoptosis, and migration was remarkably decreased via MAPK/eIF4E signaling pathway. We speculated that soluble factors secreted by MSCs might be responsible for inhibitory mechanism of NSCLC cells. By Human Gene Expression Microarray Assay and recombinant Vascular Endothelial Growth Factor 165 (VEGF165) neutralizing experiment, we verified that VEGF might be responsible for the down-regulation of proteins related to cell proliferation, anti-apoptosis, and migration by suppressing translation initiation factor eIF4E via MAPK signaling pathway. Taken together, our study demonstrated that a possible trophic factor secreted by MSCs could manipulate translation initiation of NSCLC cells via MAPK signaling pathway, and significantly affect the fate of tumor cells, which will be a new strategy for cancer therapy.
Insights
Mesenchymal stem cells (MSCs) inhibit non-small-cell lung cancer (NSCLC) growth and migration. MSCs secrete factors, including VEGF, that suppress tumor cell proliferation and migration via the MAPK/eIF4E pathway, offering a novel cancer therapy strategy.
Area of Science:
- Oncology
- Stem Cell Biology
- Molecular Biology
Background:
- Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer mortality with limited treatment options.
- Mesenchymal stem cells (MSCs) show promise in cancer therapy due to their tumor-homing and immunosuppressive properties.
- MSCs secrete trophic factors that influence tumor cell behavior.
Purpose of the Study:
- To investigate the therapeutic potential of mesenchymal stem cells (MSCs) in non-small-cell lung cancer (NSCLC).
- To elucidate the mechanisms by which MSCs affect NSCLC cell proliferation and migration.
Main Methods:
- Co-culture systems and conditioned medium experiments with NSCLC cell lines (A549, NCI-H460, SK-MES-1).
- Scratch assays to assess cell migration.
- Western blot analysis to evaluate protein expression.
- Human Gene Expression Microarray Assay and VEGF165 neutralization experiments.
Main Results:
- MSC-secreted factors inhibited NSCLC cell proliferation and migration in vitro.
- Expression of proteins involved in proliferation, anti-apoptosis, and migration was decreased via the MAPK/eIF4E signaling pathway.
- Vascular Endothelial Growth Factor (VEGF) was identified as a key factor mediating these effects by suppressing translation initiation factor eIF4E.
Conclusions:
- MSCs exert anti-tumor effects on NSCLC through paracrine signaling.
- VEGF secreted by MSCs plays a crucial role in inhibiting NSCLC progression by modulating the MAPK/eIF4E pathway.
- MSC-derived trophic factors represent a potential novel therapeutic strategy for NSCLC.

